Programmed Death-1 (PD-1) Antibody Combined With IMRT in Recurrent Nasopharyngeal Carcinoma Patients

Condition:   Recurrent Nasopharyngeal Carcinoma Interventions:   Drug: PD-1 blocking antibody;   Radiation: IMRT Sponsor:   Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials